APOLLO: Long-term Kidney Transplant Outcomes in African Ancestry
Official title: 6/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center
Funded at Weill Medical Coll of Cornell Univ · NIH-11372897 · Data updated 2026-11-12
A national network study is following kidney transplant patients and living donors with African ancestry to understand how APOL1 gene variants affect transplant success and kidney function.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | November 2, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $195,256 |
| NIH project number | 5U01DK116100-10 |
| Project ID | NIH-11372897 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults of African ancestry who are kidney transplant recipients or living kidney donors within participating centers.
✕Less likely to help
Patients not aligned with the African ancestry focus or not connected to participating transplant centers may not directly benefit.
What this research studies
This project is a collaboration across multiple transplant centers to study how APOL1 gene risk variants influence graft outcomes and kidney function in recipients and living donors with African ancestry. It uses prospective data collection, DNA analysis, and outcome tracking over time to understand risks associated with APOL1 variants. The study builds on the APOLLO consortium to share findings with transplant programs and improve patient care. Participants would contribute to data and biospecimens as part of routine transplant follow-up. Results could guide donor selection, post-transplant management, and long-term kidney health strategies for affected populations.
Why it matters
Potential benefit: If successful, the study could lead to more personalized transplant care and better long-term kidney outcomes for patients of African ancestry.
How similar studies have gone: Previous studies have shown APOL1 risk variants influence kidney disease risk, but this program aims to prospectively clarify impact on transplant outcomes.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Dadhania, Darshana — Weill Medical Coll of Cornell Univ
- Study coordinator: Dadhania, Darshana
Related research
Other NIH-funded projects on the same topics.
-
Strategies for HIV-to-HIV kidney transplants to increase organ donations
This project looks at making HIV-to-HIV kidney transplantation more common to help people with HIV get transplants faster by boosting organ donation and changing practice.
-
Biomarker-guided Immunosuppression in Kidney Transplant Patients
A multicenter study in kidney transplant recipients is testing whether a biomarker score from HLA-DR/DQ can guide changes in immunosuppression to reduce rejection risk and drug toxicity.
-
Helping the immune system accept a donated kidney in patients without prior sensitization
This project will try giving specially treated donor B cells alongside immune-sparing medicines to teach the immune systems of kidney transplant patients without prior antibodies to accept the new kidney.
-
Lowering donor-specific antibodies in sensitized kidney transplant patients
This project works to reduce harmful donor-specific antibodies in people who are sensitized and need a kidney transplant so their new organ lasts longer.
-
Reducing geographic disparities in kidney transplant access with AI and operations research
Aiming to use AI and operations research to make kidney transplant access more fair across different regions in the U.S.
-
Centralized patient coaching to boost live donor kidney transplantation
A US-wide program trains patients, caregivers, and their networks with coaching to help them pursue living donor kidney transplantation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.